Program
Budesonide
Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 692 open or running | phase 4since Sep 27, 2005 | Sep 13, 2005 | May 31, 2027phase 4 · NCT07073950 |
| Dr. Falk Pharma | 171 open or running | phase 3since Mar 7, 2006 | Mar 7, 2006 | Dec 2026phase 3 · NCT06596252 |
| Bausch Health Companies | 91 open or running | phase 4since Mar 17, 2020 | May 14, 2008 | Dec 2026phase 4 · NCT04314375 |
| Takeda | 60 open or running | phase 3since Nov 4, 2015 | Sep 29, 2008 | none ahead |
| AbbVie | 50 open or running | phase 3since Dec 5, 2007 | Oct 30, 2007 | none ahead |
| Calliditas Therapeutics AB | 51 open or running | phase 4since Nov 20, 2024 | Oct 5, 2008 | Mar 2027phase 4 · NCT06712407 |
| Intech Biopharm | 50 open or running | phase 2since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| Chenpon Pharmaceutical | 30 open or running | phase 3since Aug 24, 2026 | Aug 24, 2026 | none ahead |
| Eurofarma Laboratorios | 30 open or running | phase 3since Oct 23, 2009 | Oct 23, 2009 | none ahead |
| Novartis | 30 open or running | phase 4since Feb 15, 2013 | Feb 15, 2013 | none ahead |
| Orion Corporation, Orion Pharma | 30 open or running | phase 2since Aug 24, 2009 | Aug 24, 2009 | none ahead |
| Padagis | 30 open or running | phase 3since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| aquilon-pharmaceuticals-s-a | 20 open or running | phase 2since May 31, 2021 | May 31, 2021 | none ahead |
| bond-avillion-2-development-lp | 20 open or running | phase 3since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| Ferring Pharmaceuticals | 20 open or running | phase 3since Jan 22, 2018 | Jan 22, 2018 | none ahead |
| Ligand Pharmaceuticals | 20 open or running | phase 2since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| pari-pharma-gmbh | 20 open or running | phase 2since Sep 4, 2013 | Sep 4, 2013 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 3since Feb 12, 2014 | Feb 12, 2014 | none ahead |
| triastek-lnc | 22 open or running | phase 1since Oct 13, 2026 | Oct 13, 2026 | Dec 2026phase 1 · NCT07897240 |
| vectura-limited | 20 open or running | phase 1since Jan 12, 2018 | Jan 12, 2018 | none ahead |
| Zambon SpA | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Abbott | 10 open or running | phase 1since Jul 26, 2022 | Jul 26, 2022 | none ahead |
| Ache Laboratorios Farmaceuticos | 10 open or running | phase 3since Jul 25, 2016 | Jul 25, 2016 | none ahead |
| activaero-gmbh | 10 open or running | phase 2since Sep 10, 2010 | Sep 10, 2010 | none ahead |
| bazell-pharma-ag | 10 open or running | phase 2since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Chiesi Farmaceutici | 10 open or running | phase 3since May 18, 2007 | May 18, 2007 | none ahead |
| cipla-ltd | 10 open or running | phase 3since Mar 31, 2022 | Mar 31, 2022 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Hamad Medical | 11 open or running | phase 3since May 25, 2015 | May 25, 2015 | none ahead |
| Johnson & Johnson | 10 open or running | phase 4since Oct 17, 2019 | Oct 17, 2019 | none ahead |
| kindeva-drug-delivery | 10 open or running | phase 3since Jan 6, 2017 | Jan 6, 2017 | none ahead |
| Lunan Pharmaceutical Group | 10 open or running | no phasesince Mar 29, 2025 | Mar 29, 2025 | none ahead |
| marinomed-biotech-ag | 10 open or running | phase 3since Nov 21, 2018 | Nov 21, 2018 | none ahead |
| rafa-laboratories | 10 open or running | phase 3since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| unither-pharmaceuticals-france | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
Also a collaborator on its studies: parexel, fortrea, takeda-development-center-americas-inc, iqvia-pty-ltd, premier-inc, Hikma Pharmaceuticals, cosmo-technologies-ltd, map-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-allerga, q-pharm-pty-limited and Kyowa Kirin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 1, 2015.
- Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966 · 5,250 planned · United States, Argentina, Australia and more
- May 29, 2024Phase 1 study in Healthy VolunteerAstraZeneca · NCT06514157 · 14 enrolled · China
- Aug 19, 2024Phase 4 study in Respiratory HypersensitivityAstraZeneca · NCT06563102 · 101 enrolled · United States
- Sep 6, 2024unither-pharmaceuticals-france's first study: phase 1 study in HealthyNew to unither-pharmaceuticals-franceunither-pharmaceuticals-france · NCT06595121 · 24 enrolled · Turkey
- Sep 11, 2024Phase 3 study in Eosinophilic EsophagitisDr. Falk Pharma · NCT06596252 · 308 enrolled · United States, Spain
- Nov 20, 2024Phase 4 study in Glomerulonephritis, IGACalliditas Therapeutics AB · NCT06712407 · 60 enrolled · United States, Puerto Rico
- Mar 29, 2025Lunan Pharmaceutical Group's first study: no phase study in Bioequivalence Study in Healthy SubjectsNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06924190 · 32 enrolled · China
- Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950 · 56 planned · Germany, United Kingdom
- Feb 20, 2026Phase 1 study in AsthmaAstraZeneca · NCT07433569 · 16 enrolled · United States
- Aug 24, 2026Chenpon Pharmaceutical's first study: phase 3 study in AsthmaNew to Chenpon PharmaceuticalChenpon Pharmaceutical · NCT07790159 · 338 enrolled · China
- Aug 31, 2026Phase 2 study in AsthmaChenpon Pharmaceutical · NCT07807007 · 150 enrolled · China
- Aug 31, 2026Phase 1 study in AsthmaChenpon Pharmaceutical · NCT07804303 · 30 enrolled · China
- Oct 13, 2026triastek-lnc's first study: phase 1 study in Glomerulonephritis, IGANew to triastek-lnctriastek-lnc · NCT07897240 · 18 planned · China
- Nov 3, 2026Phase 1 study in Glomerulonephritis, IGAtriastek-lnc · NCT07925216 · 18 enrolled · China
Ahead
- Dec 2026Primary completion: phase 1 study in Glomerulonephritis, IGAtriastek-lnc · NCT07897240
- Dec 2026Primary completion: phase 3 study in Eosinophilic EsophagitisDr. Falk Pharma · NCT06596252
- Dec 2026Primary completion: phase 4 study in Colitis, UlcerativeBausch Health Companies · NCT04314375
- Jan 2027Primary completion: phase 1 study in Glomerulonephritis, IGAtriastek-lnc · NCT07925216
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
The newest 60 of 163 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07925216Glomerulonephritis, IGA · China | 1 | Active, not recruiting | triastek-lnc | Jan 2027 | 18 |
| NCT07897240Glomerulonephritis, IGA · China | 1 | Not yet recruiting | triastek-lnc | Dec 2026 | 18 |
| NCT07807007Asthma · China | 2 | Completed | Chenpon Pharmaceutical | Aug 3, 2026 | 150 |
| NCT07804303Asthma · China | 1 | Completed | Chenpon Pharmaceutical | Jan 22, 2024 | 30 |
| NCT07790159Asthma · China | 3 | Completed | Chenpon Pharmaceutical | Sep 27, 2024 | 338 |
| NCT07433569Asthma · United States | 1 | Completed | AstraZeneca | Jun 26, 2026 | 16 |
| NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom | 4 | Recruiting | AstraZeneca | May 31, 2027 | 56 |
| NCT06924190Bioequivalence Study in Healthy Subjects · China | – | Completed | Lunan Pharmaceutical Group | Jan 20, 2025 | 32 |
| NCT06712407Glomerulonephritis, IGA · United States, Puerto Rico | 4 | Active, not recruiting | Calliditas Therapeutics AB | Mar 2027 | 60 |
| NCT06596252Eosinophilic Esophagitis · United States, Spain | 3 | Active, not recruiting | Dr. Falk Pharma | Dec 2026 | 308 |
| NCT06595121Healthy · Turkey | 1 | Completed | unither-pharmaceuticals-france | Sep 16, 2024 | 24 |
| NCT06563102Respiratory Hypersensitivity · United States | 4 | Completed | AstraZeneca | Feb 24, 2026 | 101 |
| NCT06514157Healthy Volunteer · China | 1 | Completed | AstraZeneca | Sep 9, 2024 | 14 |
| NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 3, 2027 | 5,250 |
| NCT06268301Healthy Volunteers · United States | 1 | Completed | Takeda | Feb 17, 2023 | 20 |
| NCT06245551Asthma, Exercise-Induced · Russia | 3 | Completed | AstraZeneca | Jun 29, 2024 | 64 |
| NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | AstraZeneca | Jan 22, 2026 | 171 |
| NCT05970263Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | AstraZeneca | Dec 31, 2025 | 0 |
| NCT05755906Asthma · United States, Canada, Czechia and more | 3 | Completed | AstraZeneca | Nov 19, 2024 | 374 |
| NCT05519514Healthy Subjects · India | 1 | Completed | Abbott | Aug 8, 2021 | 56 |
| NCT05429775Healthy Volunteers · United Kingdom | 1 | Completed | Novartis | Jan 29, 2019 | 12 |
| NCT05322707Asthma · United States | 3 | Completed | cipla-ltd | Aug 15, 2023 | 1,485 |
| NCT05202262Asthma · United States, Canada, Germany and more | 3 | Completed | AstraZeneca | Feb 26, 2025 | 645 |
| NCT05214599Eosinophilic Esophagitis | 2 | Withdrawn | bazell-pharma-ag | Nov 2024 | 0 |
| NCT05148312Pharmacokinetics · Bulgaria | 1 | Completed | aquilon-pharmaceuticals-s-a | Dec 24, 2021 | 29 |
| NCT04933383Asthma · Belgium | 2 | Completed | aquilon-pharmaceuticals-s-a | Dec 31, 2022 | 23 |
| NCT04854538Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Oct 1, 2020 | 30 |
| NCT04609904Asthma · United States, Brazil, China and more | 3 | Completed | AstraZeneca | Mar 20, 2025 | 2,187 |
| NCT04609878Asthma · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Mar 21, 2025 | 2,274 |
| NCT04541043Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Completed | Calliditas Therapeutics AB | Feb 26, 2024 | 119 |
| NCT04494321Asthma · Taiwan | 1 | Completed | Intech Biopharm | Nov 17, 2017 | 99 |
| NCT04314375Colitis, Ulcerative · United States | 4 | Recruiting | Bausch Health Companies | Dec 2026 | 70 |
| NCT04234464Asthma, Exercise-Induced · United States | 3 | Completed | bond-avillion-2-development-lp | Aug 28, 2020 | 60 |
| NCT04132570Rhinitis · China | 4 | Completed | Johnson & Johnson | Jan 22, 2020 | 206 |
| NCT04080713Healthy · India | 1 | Completed | Ferring Pharmaceuticals | Sep 25, 2019 | 24 |
| NCT04032834Asthma · United States | 1 | Completed | vectura-limited | May 22, 2017 | 34 |
| NCT03769090Asthma · United States, Argentina, Canada and more | 3 | Completed | bond-avillion-2-development-lp | Aug 19, 2021 | 3,132 |
| NCT03755557Rhinitis, Allergic · Austria | 3 | Completed | marinomed-biotech-ag | Apr 5, 2019 | 82 |
| NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands | 3 | Completed | AstraZeneca | Nov 11, 2019 | 23 |
| NCT03643965Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Completed | Calliditas Therapeutics AB | Jul 10, 2023 | 365 |
| NCT03412682Colitis, Ulcerative · Japan | 3 | Completed | Ferring Pharmaceuticals | May 11, 2020 | 274 |
| NCT03421730Respiratory Sounds · United States | 1 | Completed | vectura-limited | Mar 21, 2018 | 17 |
| NCT03245840Eosinophilic Esophagitis · United States | 3 | Terminated | Takeda | Apr 26, 2022 | 133 |
| NCT03015259Asthma · United States | 3 | Completed | kindeva-drug-delivery | Feb 8, 2018 | 1,762 |
| NCT02972866Rhinitis, Allergic, Perennial · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | Nov 2019 | 0 |
| NCT02853578Asthma · Brazil | 3 | Suspended | Ache Laboratorios Farmaceuticos | Oct 2020 | 80 |
| NCT02850484Asthma | 1 | Completed | Intech Biopharm | May 2016 | 99 |
| NCT02800824Healthy | 1 | Completed | Padagis | Jun 2016 | |
| NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | AstraZeneca | Dec 1, 2017 | 2,389 |
| NCT02736409Eosinophilic Esophagitis · United States | 3 | Completed | Takeda | Nov 12, 2019 | 219 |
| NCT03262012Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Jun 15, 2018 | 416 |
| NCT03073057Asthma · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Mar 2016 | 20 |
| NCT02631941Asthma · United Kingdom | 1 | Completed | Zambon SpA | Jul 2016 | 91 |
| NCT02605837Eosinophilic Esophagitis · United States | 3 | Completed | Takeda | Jan 24, 2019 | 318 |
| NCT02550418Colitis, Ulcerative · Germany | 2 | Completed | Dr. Falk Pharma | Mar 2017 | 60 |
| NCT02536508Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | AstraZeneca | Sep 12, 2017 | 627 |
| NCT02533505Pulmonary Disease, Chronic Obstructive · United States | 4 | Completed | AstraZeneca | Aug 12, 2016 | 51 |
| NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | AstraZeneca | Jan 5, 2018 | 1,902 |
| NCT02493335Eosinophilic Esophagitis · Germany | 3 | Completed | Dr. Falk Pharma | Nov 28, 2018 | 204 |
| NCT02495168Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | May 31, 2018 | 1,714 |
How it is read
Names in the registry
- “Budesonide”, 45 entries
- “budesonide”, 18 entries
- “budesonide/formoterol”, 10 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
- “BFF MDI 320/9.6 μg”, 5 entries
Conditions, from the studies’ own filings
- Asthma, 75 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Eosinophilic Esophagitis, 10 studies
- Colitis, Ulcerative, 9 studies
- Glomerulonephritis, IGA, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.